Results 151 to 160 of about 9,430 (168)

Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease

Clinical Rheumatology, 2017
Antonio Vitale, Giacomo Emmi, Giuseppe Lopalco   +2 more
exaly  

Pharmacokinetics and Safety of Golimumab, a Fully Human Anti-TNF-α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis

Journal of Clinical Pharmacology, 2007
Roy Fleischmann, Zhenhua Xu, Qun Jiao
exaly  

Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis

Journal of Clinical Pharmacology, 2019
Omoniyi J Adedokun, Chuanpu Hu, Zhenhua Xu   +2 more
exaly  

Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

Inflammatory Bowel Diseases, 2017
CARLOS Taxonera, Federico Bertoletti, Lara Arias   +2 more
exaly  

Golimumab in the treatment of ulcerative colitis

Therapeutic Advances in Gastroenterology, 2019
Mark A Samaan, Peter M Irving
exaly  

Long-term Treatment with Golimumab for Severe Uveitis

Ocular Immunology and Inflammation, 2014
Elisabetta Miserocchi, Giulio Modorati, Pier Luigi Meroni   +2 more
exaly  

Subcutaneous Bioavailability of Golimumab at 3 Different Injection Sites in Healthy Subjects

Journal of Clinical Pharmacology, 2010
Zhenhua Xu, Yanli Zhuang, Hugh M Davis
exaly  

Golimumab

Reactions Weekly, 2014
openaire   +2 more sources

Pharmacokinetic Bridging Approach for Developing Biologics-delivery Devices: A Case Study With a Golimumab Autoinjector

Clinical Therapeutics, 2015
Zhenhua Xu, Lilianne Kim, Yanli Zhuang   +2 more
exaly  

Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study

Modern Rheumatology, 2016
Y Yonemoto, Kimihiko Takeuchi, Tetsuya Kaneko   +2 more
exaly